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What is known about this topic?
− Streptococcus pneumoniae (pneumococcus) has evolved various strategies to encounter humans and establish itself in different host niches. For instance, pneumococci interact with vitronectin and Factor H. Both human glycoproteins are fluid-phase complement inhibitors, bind to integrins or to the extracellular matrix of various human tissues, and vitronectin is additionally implicated in haemostasis and angiogenesis.
− Serotype 3 Streptococcus pneumoniae strains express Hic, a surface-exposed PspClike protein, which was shown to recruit the human complement inhibitor protein Factor H to evade complement-mediated phagocytosis.
What does this paper add?
− Hic was identified as vitronectin-binding adhesin of serotype 3 pneumococci.
− Factor H and vitronectin simultaneously bind to Hic and the binding sites for Factor H and vitronectin within the Hic molecule were characterised. In addition, the Hicbinding site was localised to the C-terminal heparin-binding domain within human vitronectin. Importantly, vitronectin bound to Hic efficiently inhibited the terminal complement pathway.
− By binding Factor H and vitronectin, Hic may contribute to both immune evasion at different levels of the complement cascade and pneumococcal adhesion.
Introduction
Gram-positive Streptococcus pneumoniae (S. pneumoniae, pneumococci) are often carried as harmless commensals in the human nasopharynx. However, pneumococci have evolved several sophisticated strategies to evade the immune system in order to cause mucosal and respiratory diseases such as sinusitis, otitis media and pneumonia. They are also responsible for severe life-threatening systemic diseases such as pneumococcal sepsis and meningitis associated with vascular injury due to pneumococcal pneumolysin, coagulation and complement activation, production of reactive oxygen and nitrogen species, and secretion of pro-inflammatory cytokines (1-3). The polysaccharide capsule, which occurs in at least 94 varieties, is one main pneumococcal virulence determinant (4) . However, surface-exposed adhesive proteins are also considered being important virulence factors (5, 6) . In spite of the ability to treat and prevent pneumococcal infections with antibiotics and conjugate vaccines, the incidence of invasive pneumococcal disease remains high. Risk groups are especially children <5 years of age, the elderly, and immunocompromised individuals (7) . Serotype 3 pneumococci belong to the most frequent strains in clinical isolates and are associated with invasive diseases in young children and high case-fatality rates (8) (9) (10) . The resistance of pneumococci, and especially serotype 3, to complement-mediated opsonization and phagocytosis is closely related to the recruitment of complement inhibitor Factor H to the bacterial surface (11) . Factor H (FH), a 150-kDa single chain plasma glycoprotein, is composed of 20 modules referred to as short consensus repeat (SCR) and complement control protein (CCP), respectively. Factor H regulates the alternative pathway (AP) of complement at the C3 convertase level (12) . In addition, Factor H binds to integrins via its arginineglycine-aspartate (Arg-Gly-Asp, RGD) motif and to surface-associated molecules, such as glycosaminoglycans (12, 13) . Pneumococci exploit host-cell bound Factor H for adherence and dissemination, and they recruit soluble Factor H to inhibit complement activation during infections via the pneumococcal surface protein C (PspC) (13) (14) (15) (16) . Based on their anchorage to the bacterial surface, the 11 distinct PspC subtypes are classified into two subgroups.
Classical PspC proteins (subtypes 1-6, members of subgroup I) possess a conserved Cterminal choline-binding domain, which enables non-covalent attachment to phosphorylcholine moieties of the surface-displayed teichoic acids. In contrast, non-classical or PspC-like proteins (subtypes 7-11, members of subgroup II) harbor a conserved C-terminal pentapeptide sequence (LPxTG-motif), which is cleaved by the transpeptidase sortase A and covalently linked to the bacterial peptidoglycan (17) . Only little is known on the allelic distribution of pspC proteins among serotype 3 pneumococci but it is suggested that either group 8 or group 11 PspC proteins are expressed (17) (F. Iannelli, personal communication).
PspC protein group 11 so far consists of four members (PspC11. [1] [2] [3] [4] , which show 100% nucleotide and amino acid identity in their N-terminal region and C-terminal LPSTG-containing part but vary in their proline-rich region (17) .
In serotype 3 strain A66 a pspC locus-encoded surface-exposed protein was identified as major Factor H-binding adhesin and termed Hic (factor H-binding inhibitor of complement, class II PspC, PspC11.4) (11, 18, 19) . Hic is a ~70-kDa protein, composed of a 37-aa leader peptide, a long stretch with regions of predicted α-helical conformation, followed by 25 proline-rich repeats and a sortase signal motif (LPSTG) for covalent anchorage to the pneumococcal cell wall (17) . The N-terminal part (aa 38-155) of Hic shows considerable sequence homology to the Factor H-binding region (residues 38-158) of classical PspC proteins, suggesting that Hic and PspC share a sequence motif with Factor H-binding activity (17, 18) .
Similar to Factor H, human vitronectin (Vn) plays a role in pneumococcal pathogenesis.
Monomeric vitronectin is an abundant plasma glycoprotein of ~75 kDa promoting microvascular angiogenesis, regulating the fibrinolytic, coagulation and plasminogen activation system, and inhibiting the terminal complement pathway both in fluid phase and on cell surfaces. In contrast, multimeric vitronectin constitutes the extracellular matrix of different tissues promoting cell adhesion, spreading and differentiation (20) . Vitronectin consists of an N-terminal somatomedin-B domain, an RGD motif as recognition site for integrins, four hemopexin-like and three heparin-binding domains (HBD1: aa 82-137; HBD2: aa 175-219; HBD3: aa 348-361) (20, 21) . S. pneumoniae expressing class I PspC proteins were shown to recruit vitronectin efficiently to their surface possibly preventing formation of the terminal complement complex (TCC) during the intimate contact of pneumococci with the human host (22) (23) (24) . In addition, pneumococci exploit host-cell-bound multimeric vitronectin to adhere to epithelial cells of the respiratory tract, thereby activating α v β 3 -integrin signaling pathways, triggering cytoskeleton reorganization, and subsequently promoting pneumococcal internalization (22) .
The purpose of this study was to analyse vitronectin-binding to PspC11-expressing serotype 3 pneumococci and to characterise the interaction of Hic (PspC11.4) with the human plasma glycoproteins vitronectin and Factor H.
Material and methods

Reagents and antibodies
DNA and protein markers were from Fermentas (Thermo Fisher Scientific, MA, USA) or SERVA (Germany). Coomassie brilliant blue R250 and bovine serum albumin (BSA) were purchased from Roth (Germany). Heparin (potassium salt) was purchased from ICN Biomedicals (OH, USA). Human Factor H was provided by Calbiochem (Merck Millipore, Germany) or Complement Technology (TX, USA). Multimeric vitronectin was obtained from Millipore (Merck Millipore, Germany). Biotin-labeled multimeric vitronectin was provided by Loxo (Germany). Recombinant C-terminally His 6 -tagged multimeric vitronectin fragments were heterologously expressed in HEK293T cells and purified as described previously (25) . 
DNA sequencing and analysis
Chromosomal DNA of S. pneumoniae was isolated and purified using a standard Phenol/Chloroform extraction method as described previously (26) . DNA amplification was performed by PCR using the primers NNHic and CCHic ( (23, 27) . Expression of Hic was induced by adding Nisin (0.1 µg/ml) to mid-log grown recombinant lactococci and verified by flow cytometry using mouse anti-Hic2 antiserum.
Cloning, expression and purification of N-terminally His 6 -tagged Hic protein derivatives
The S. pneumoniae A66 DNA sequences coding for the four Hic protein derivatives (Fig. 3B) were PCR amplified using the primers listed in Table 3 and chromosomal DNA as template.
The PCR products were cloned after NheI/HindIII (NEB, MA, USA) digestion into the similarly digested pTP1 vector (28) resulting in the plasmids pHic2, pHic5, pHic6, and pHic7, respectively ( (1 µg/ml) was added to the pneumococci. After extensive washing, bacteria were incubated with Alexa Fluor 488-conjugated streptavidin (2 µg/ml). Finally, bacteria were washed and fixed using 1% PFA/0.5% FCS/PBS overnight at 4°C. The samples were analysed using a 
Enzyme-linked immunosorbent assay (ELISA)
Microtiter plates (F96, Polysorb TM , Nunc, Thermo Fisher Scientific, MA, USA) were coated with S. pneumoniae Hic constructs Hic2, Hic5, Hic6, Hic7, and BSA, as control, over night at 4°C. The plates were washed four times with 0.05% Tween20/PBS (pH 7.4) and blocked for 1 h at RT with 2% BSA/0.1% Tween20/PBS (blocking buffer). The plates were then incubated for 1 h at RT with vitronectin, the various recombinant vitronectin constructs or Factor H diluted in blocking buffer. Thereafter, wells were washed and incubated with a rabbit anti-human vitronectin antiserum (1:1000 in blocking buffer) or goat anti-human Factor H antiserum (1:500 in blocking buffer), followed by HRP-conjugated anti-rabbit antibodies or HRP-conjugated anti-goat antibodies (1:1000 in blocking buffer). The assay was also performed vice versa. Vitronectin, Factor H, recombinant vitronectin fragments or BSA, as control, were immobilised on microtiter plates (F96, Maxisorb TM , Nunc, Thermo Fisher Scientific, MA, USA), blocked, and incubated with recombinant Hic peptides diluted in blocking buffer. Thereafter, wells were incubated with mouse anti-Hic2 antiserum (in blocking buffer) followed by HRP-conjugated anti-mouse IgG (1:1000 in blocking buffer). In inhibition assays, the binding of a constant concentration of vitronectin (5 µg/ml) was measured to immobilised Hic2 in the presence of increasing concentrations of NaCl (100 µl of 0-1.0 M), heparin (100 µl of 0-5000 µg/ml), heparan sulfate (100 µl of 0-100 µg/ml), chondroitin sulfate A (100 µl of 0-1000 µg/ml), and hyaluronic acid (100 µl of 0-1000 µg/ml), respectively. In competition assays, vitronectin, used at different concentrations (100 µl of 0-1 µg/ml), was incubated with a constant amount of Factor H (10 µg/ml) and vitronectin-binding to immobilised Hic2 was measured. Similarly, Factor H was used at different concentrations (0-1 µg/ml), combined with a constant amount of vitronectin (5 µg/ml), and Factor H-binding to immobilised Hic2 was assayed. The reactions were developed with OPD and the absorbance was measured at 492 nm.
Surface plasmon resonance (SPR)
Direct protein-protein interactions were analysed by surface plasmon resonance (SPR) using a Biacore T100 optical biosensor (GE Healthcare, Germany). Covalent immobilization of vitronectin (5 µg/ml), Vn(80-396), Vn(80-339), and Vn(80-229) (each 25 µg/ml), or Hic2 (80 µg/ml) onto an NHS/EDC-activated carboxymethyl-dextran (CM5) sensor chip was performed as described previously (22, 
Microscale Thermophoresis (MST)
Molecular protein-protein interactions in solution were analysed by microscale thermophoresis. Human vitronectin at a concentration of 13.3 µM was labeled with NT-647 using Nano Temper´s protein labeling kit RED-NHS (NanoTemper Technologies, Germany).
A series of 1:1 dilutions (0.001-40 µM) of unlabeled Hic2 or BSA, as control, was added to 12.5 nM of NT-647-labeled vitronectin. Samples were diluted in MST buffer (50 mM TrisHCl, 150 mM NaCl, 10 mM MgCl 2 and 0.05% Tween20, pH 7.6). Thermophoresis was measured at 60% LED power and 40% MST power for 30 s in a Monilith NT.115 instrument (NanoTemper Technologies, Germany). All measurements were performed at room temperature using hydrophilic capillaries.
Binding of bacteria to immobilised human proteins
Microtiter plates (F96, MaxiSorp TM , Nunc, Thermo Fisher Scientific, MA, USA) were coated with human vitronectin, recombinant vitronectin fragments, Factor H, or BSA in 0.1 M sodium carbonate-bicarbonate buffer (pH 9.2) at 4°C overnight. The surfaces of the wells were washed and subsequently blocked with 1% BSA/PBS (pH 7.4) for at least 3 h at RT.
Labeling of bacteria with FITC was performed as described previously (29) . Extensively washed FITC-labeled bacteria (100 µl of 2 x 10 8 bacteria) were added to the washed wells and incubated for 1 h at 37°C. Fluorescence was measured at 485 nm/520 nm (excitation/emission) using a microplate reader (Fluostar Omega, BMG Labtech, Germany)
prior to the first washing step (total fluorescence of inoculated bacteria) and after each of the four washing steps with 100 µl PBS (fluorescence of bound bacteria).
TCC formation assays
Microtiter plates (F96, Medisorb TM , Nunc, Thermo Fisher Scientific, MA, USA) were coated with Hic2 (100 µl of 5 µg/ml) or Factor H (100 µl of 50 µg/ml) over night at 4°C in PBS (pH 7.4). After washing with 0.05% Tween20/PBS (pH 7.4), the wells were blocked for 1 h at RT with 2% BSA/0.05% Tween20/PBS. Thereafter, vitronectin (100 µl of 0-50 µg/ml) was added to immobilised Hic2 and incubated for 1 h at RT. After washing, the terminal complement proteins C5b-6 (1.5 µg/ml) and C7 (1 µg/ml) were added. Following incubation for 10 min at RT, C8 (0.2 µg/ml) and C9 (1 µg/ml) were added to a total volume of 100 µl and the mixture was further incubated for 30 min at 37°C. TCC assembly was detected using mouse anti-human C5b-9 mAb and HRP-conjugated swine anti-mouse antibodies. The reaction was developed with OPD and the absorbance was measured at 492 nm.
To investigate whether vitronectin inhibits TCC formation on the pneumococcal surface, pneumococci were incubated with vitronectin (0-25 µg/ml) for 30 min at RT. Bacteria were washed with 1% BSA/PBS, C5b-6 (1 µg/ml) was added for 5 min at RT and thereafter C7
(1 µg/ml), C8 (0.4 µg/ml) and C9 (1 µg/ml) were added. Following incubation for 30 min at 37°C, deposited C5b-9 was detected with mouse anti-human C5b-9 mAb and Alexa Fluor 647-conjugated swine anti-mouse antibodies. After washings the binding was analysed using a FACScan LRII™ flow cytometer and data acquisition was performed using FlowJo (Becton Dickinson, NJ, USA). Data analysis and gating of bacteria was conducted as described above.
Statistical analysis
All data are reported as mean ± SD. Results were statistically analysed using the unpaired two-tailed Student's test. A P-value ≤0.05 was considered statistically significant.
Results
Vitronectin binds to pspC11-expressing bacteria
Given the functional diversity of various pneumococcal surface-exposed proteins (e.g., class I PspC interacting with Factor H, C4b-binding protein (C4BP), secretory component of the human pIgR, vitronectin, and 67kDa-laminin receptor) (6, 15, 23, (30) (31) (32) , we were interested whether the Factor H-binding protein Hic and related PspC11 proteins also bind vitronectin.
Therefore, we first screened for pspC11 in genomic DNA samples of serotype 3 clinical isolates received from the NRZ, Germany (Table 2) . By using the primers Hic4F and Hic5R (Table 3) , a PCR fragment specific for pspC11 (17) was amplified from chromosomal DNA of S. pneumoniae A66 and the serotype 3 clinical isolates, except for N025, whereas no PCR product was obtained from D39 genomic DNA (data not shown). The PCR products of the clinical isolates correspond to nucleotides 112-796 or amino acids 38-266 of the annotated sequences for Hic in S. pneumoniae A66 and related PspC11 proteins (Table 4) , suggesting a high conservation of this protein domain among PspC11 proteins. To define the pspC11 allele in the serotype 3 clinical isolates, the complete pspC11 gene was amplified with the primer pair NNHic and CCHic, sequenced and aligned using the primers listed in Table 3 . Strikingly, when aligned against the amino acid sequence of Hic (PspC11.4), the N-terminal domain and the C-terminal domain, including the LPSTG motif, showed 100% identity, whereas the proline-rich domains varied in length and sequence.
In order to explore vitronectin-binding activity, strain A66 and pspC11-positive serotype 3
clinical isolates were pretreated with paraformaldehyde and glutaraldehyde to reduce the amount of capsule hindering protein-binding (15, 22, 24, 26, 29) , incubated with increasing amounts of soluble vitronectin, and bound vitronectin was measured by flow cytometry. In addition, A66Δcps and A66 ccv , a low-encapsulated variant of A66 recovered from the intracellular compartment of epithelial cells (24) , were examined for binding of vitronectin.
Vitronectin bound dose-dependently to the surface of all tested pneumococcal strains (Fig. 1, A and C). In addition, Factor H-binding to A66 and the clinical isolates was assayed. Factor H, similar to vitronectin, was recruited in a dose-dependent fashion (Fig. 1B) . To prove that treatment of pneumococci with aldehydes does not interfere with the recruitment of human plasma proteins to the pneumococcal surface, A66Δcps was treated with paraformaldehyde and glutaraldehyde and thereafter incubated with vitronectin and Factor H. Both human glycoproteins bound with comparable intensity to A66Δcps when compared with untreated pneumococci (data not shown).
To verify if Hic recruits vitronectin to the pneumococcal surface, vitronectin-binding to A66Δcps and its isogenic hic deletion mutant was analysed. Recruitment of vitronectin to the surface of Hic-deficient A66Δcps was substantially reduced, but not completely diminished, compared with its isogenic A66Δcps strain. In contrast, binding of Factor H was abolished in the Hic-deficient mutant (Fig. 1, D and E) . In a complementary approach, pretreatment of pneumococci with specific anti-Hic serum diminished binding of vitronectin and Factor H, whereas the control serum showed no effect (Fig. 1F) . ( Fig. 1G) .
N-linked glycosylation is not required for binding of vitronectin and Factor H to pneumococcal Hic
To determine whether oligo-saccharide residues of vitronectin and Factor H are involved in the interaction with Hic, pneumococci were incubated with N-glycosidase F-treated or untreated vitronectin and Factor H, respectively, or with serum obtained from patients with glycosylation defects. Binding of deglycosylated vitronectin and Factor H to the pneumococcal surface was similar and did not differ significantly from the unmodified protein. Likewise, binding of Factor H or vitronectin derived from serum of patients with glycosylation defects was not significantly altered compared to normal human serum (Fig. 2) .
Vitronectin and Factor H simultaneously bind to Hic
The PspC-like proteins of S. pneumoniae serotype 3 exhibit both vitronectin-and Factor Hbinding activity. It has been suggested that the Factor H-binding region is localised to the N-terminal part of Hic, which displays high sequence homology to classical PspC proteins (11, 18) . To determine whether both human glycoproteins bind simultaneously or compete for binding to Hic, binding of biotin-labeled vitronectin to A66Δcps in presence of Factor H was assayed by flow cytometry. In this approach, Factor H did not inhibit the recruitment of biotinylated vitronectin to the pneumococcal surface (Fig. 3A) . Furthermore, the N-terminal part of Hic, comprising amino acid residues 38 to 245, was produced as His 6 -tagged fragment
Hic2 in E. coli (Fig. 3B) , and employed in competitive ELISA. Vitronectin and Factor H simultaneously bound to immobilised Hic2, even when both proteins were applied at excess concentrations compared with the molar ratio that corresponds to their plasma levels, i.e.,
vitronectin:Factor H of 1:2.5 (Fig. 3, C and D) . These results demonstrate that vitronectin and Factor H recognise different regions within the Hic protein.
Localization of the vitronectin and Factor H binding regions within Hic
To further characterise the Hic-vitronectin interaction and to localise the vitronectin-and
Factor H-binding region in the Hic protein, amino-and carboxy-terminal truncated fragments of the mature Hic protein were produced in E. coli (Fig. 3B) and employed in binding studies.
In a first attempt, binding of soluble Factor H and vitronectin, respectively, to immobilised Hic fragments was assayed by ELISA. Factor H bound dose-dependently to the Hic peptides Hic2, Hic5, and Hic6, whereas no binding to immobilised Hic7 was detected (Fig. 4A ).
In contrast, vitronectin bound dose-dependently to the Hic fragments Hic2, Hic5, and Hic7, whereas only minor binding was observed to Hic6 (Fig. 4B) (Fig. 4G) .
Binding of Hic to vitronectin is mediated by ionic interactions and inhibited by glycosaminoglycans
To determine if ionic forces play a role in the interaction of Hic with vitronectin, the effect of sodium chloride on vitronectin-binding to Hic was assayed. Sodium chloride significantly affected binding of vitronectin to immobilised Hic2, e.g., at a concentration of 125 mM, NaCl reduced vitronectin-binding to Hic2 by almost 30% (Fig. 5A ). To verify whether Hic competes with glycosaminoglycans for binding to vitronectin (20) , the effect of heparin, heparan sulfate, chondroitin sulfate A, and hyaluronic acid on vitronectin-binding to immobilised Hic2 was investigated. In contrast to non-sulfated hyaluronic acid (Fig. 5E ), the sulfated glycosaminoglycans heparin, heparan sulfate and chondroitin sulfate A dosedependently inhibited the Hic2-vitronectin interaction (Fig. 5, B-D) . For instance, heparin used at a concentration of 1 µg/ml decreased vitronectin-binding by ~40% (Fig. 5B) . These data suggest a charge-dependent interaction of Hic with the heparin-binding domain(s) of vitronectin.
The Hic-binding region is located within the C-terminal HBD of vitronectin
To pinpoint the heparin-binding domain (HBD) of vitronectin recognised by Hic, a series of truncated fragments spanning the amino acid residues 80-396 of vitronectin were heterologously produced in HEK293T cells ( 
Binding of Hic to immobilised vitronectin requires an N-terminal region to the
HBD3
The important role of human serum and extracellular matrix proteins as molecular bridges for S. pneumoniae and other human pathogens to integrin receptors on host cells has been studied extensively (6, 22, 33, 34 (Fig. 7A) . Interestingly, the mutant A66∆cps∆hic showed a strong reduction in adherence to immobilised vitronectin. Binding of this mutant to immobilised Factor H was also significantly reduced, however, the reduction was less pronounced when compared to vitronectin (Fig. 7A ). In addition, recombinant lactococci exposing Hic on their surface efficiently bound to immobilised vitronectin and Factor H, compared to control lactococci carrying an empty vector (Fig. 7B) . In order to verify whether the interaction of Hic with (Fig. 7E) . In SPR experiments, the vitronectin-binding Hic7 derivative shows considerable binding activities to immobilised Vn(80-396) and Vn(80-339), but did not reveal any interaction with immobilised Vn(80-229) (Fig. 7F) . These data strongly suggest that the linker region between HBD2 and HBD3 is involved in Hic-binding to immobilised vitronectin.
The vitronectin-Hic complex inhibits TCC formation
The ability of vitronectin bound to Hic to impede TCC formation was assessed by ELISA.
Vitronectin bound to immobilised Hic2 significantly reduced the generation of TCC. In contrast, Factor H did not affect TCC formation (Fig. 8A) . In a complementary approach, TCC deposition on the surface of A66Δcps and its isogenic hic mutant in the presence of increasing concentrations of vitronectin was analysed by flow cytometry. Vitronectin at a concentration of 25 µg/ml significantly inhibited TCC formation on the surface of both pneumococcal strains (Fig. 8B) . Taken together, vitronectin bound to the pneumococcal surface -and to Hic -remains active and regulates the terminal complement pathway (33) .
Discussion
The efficiency of S. pneumoniae to cause life-threatening infections is closely related to their ability to recruit human glycoproteins that interfere with the coagulation and complement system, facilitate attachment to and transmigration through tissue barriers, and modulate inflammatory responses (5, 6, 10) . Serotype 3 strain A66 recruits the complement inhibitor protein Factor H, via surface-exposed Hic, which renders the bacteria resistant to opsonophagocytosis (11, 18) . This study demonstrates that Hic, a PspC11 subtype, and related PspC11 proteins specifically and simultaneously interact with vitronectin and Factor H. Both human glycoproteins are fluid-phase complement inhibitors, bind to integrins or to the extracellular matrix of various human tissues, and vitronectin is additionally implicated in haemostasis and angiogenesis (12, 20, 35) .
Nucleotide and amino acid sequence analysis of the pspC11 gene of serotype 3 clinical isolates revealed four new PspC11 alleles (Table 4) , whose N-terminal and C-terminal LPSTG-containing parts were highly conserved when compared with Hic (PspC11.4). In contrast, the proline-rich region showed considerable variability in length and amino acid composition. This has previously been shown for other PspC alleles and PspA, another surface-exposed choline-binding protein and important virulence factor of S. pneumoniae (17) . Despite the diversity, the proline-rich regions of PspC and PspA are highly conserved compared to the N-terminal parts of both protein families and highly immunogenic, which has raised interest in the development of protein-based vaccines against pneumococcal infections (17, 36) .
Binding of vitronectin and Factor H to PspC11-expressing clinical isolates and the A66
reference strain was monitored by flow cytometry. Both human plasma glycoproteins bound in a dose-dependent manner to the pneumococcal surface, after treatment with aldehydes ( Fig.   1, A and B) . However, the ability to recruit vitronectin and Factor H significantly increased when the capsular polysaccharide was absent or massively reduced as shown for the capsule mutant and the low-encapsulated variant of A66 (Fig. 1C) . This effect has also previously been reported for vitronectin-binding to pneumococci expressing choline-bound PspC and for Factor H-binding to A66 (15, 22) . Vitronectin-binding to the hic mutant was significantly reduced, though the decrease was less pronounced compared to the binding of Factor H and to the pretreatment of A66∆cps with anti-Hic antiserum (Fig. 1, D-F) . The anti-Hic antiserum specifically recognizes surface-exposed Hic. However, the antibodies might also sterically impede binding of vitronectin to other putative binding partners resulting in the dramatic reduction of vitronectin acquisition (Fig. 1F) . These data suggest that S. pneumoniae A66 expresses another yet unknown protein(s) binding to soluble vitronectin.
However, the capacity of Hic to serve as a vitronectin-and Factor H-binding protein of S. pneumoniae was verified by using a heterologous L. lactis expression system. Lactococci expressing Hic on their surface showed significant vitronectin-and Factor H-binding activity (Fig. 1G) . The expression of surface-exposed proteins cooperatively recognising the same host factor is a general strategy among pneumococci and other human pathogens. Acquisition of human plasma proteins and immune inhibitors facilitate colonization and survival, as was demonstrated, for instance, for fibronectin-binding adhesins of S. pneumoniae as well as
vitronectin-binding proteins of Haemophilus influenzae and Neisseria meningitidis (37-45).
Deglycosylated vitronectin and Factor H retained their Hic-binding characteristics indicating that oligosaccharide residues within both glycoproteins are not required for recognition of vitronectin and Factor H by Hic-expressing pneumococci (Fig. 2) . This was also demonstrated for vitronectin-binding to UspA2 of M. catarrhalis (46) .
Factor H and vitronectin simultaneously interact with Hic either exposed on the pneumococcal surface or immobilised on a microtiter plate (Fig. 3) (11, 18) . PspC proteins showing >70% sequence identity (Fig. 4) (11, 18) . A recent study demonstrated that classical PspC proteins interact with vitronectin via their repeat domains (referred to as R1 and R2). It was reported that the presence of two interconnected repeat domains, represented by PspC3 proteins, rather than one repeat domain, represented by PspC2 proteins, increases vitronectin-binding efficiency (23) . Hic and related PspC11 proteins share only minor sequence and structural homologies to the repeat domain of PspC2 and PspC3 proteins.
This suggests that Hic and related PspC11 proteins have adopted a binding mode distinct from classical PspC molecules. The molecular interaction of Hic with vitronectin was analysed in detail and the affinity was in the micromolar range (Fig. 4, C-F) . Comparable dissociation constants were reported for other bacterial vitronectin-binding proteins, such as H. influenzae
Protein E (PE) and F (PF) and M. catarrhalis UspA2 (42, 43, 46) .
Several human bacterial pathogens bind vitronectin via its heparin-binding domain(s)
(HBDs), including PE, PF, and UspA2, as well as Opc of N. meningitides (25, 43, 45, 46) .
The decoration of the bacterial surface with vitronectin or the exploitation of host-cell bound vitronectin facilitates complement evasion and adherence to host cells, respectively (33) .
Sodium chloride and negatively charged sulfated glycosaminoglycans inhibited the interaction between Hic and vitronectin ( Fig. 5) , demonstrating the importance of charged amino acids for the interaction of Hic with at least one of the three HBDs of vitronectin. This has also been demonstrated for pneumococci expressing classical PspC and other pathogenic bacteria such as group B streptococci, staphylococci and H. influenzae (19, 23, 43, 47) . To pinpoint the HBD recognised by Hic, a series of recombinant vitronectin fragments was used. Vitronectin fragments devoid of the complete C-terminal heparin-binding domain (HBD3) failed to interact with Hic (Fig. 6) . It is noteworthy that this binding behavior resembles the interaction of classical PspC and other pathogenic bacteria with vitronectin (23, 25, 33, 43) .
As mentioned, Hic interacts with both the soluble and immobilised form of vitronectin (Fig.   6, Fig. 7, A and B) . However, the binding studies suggested that immobilised vitronectin exposes an additional recognition site for Hic because also vitronectin fragment Vn(80-353), which lacks the C-terminal HBD3, bound to immobilised Hic but not to the soluble form (Fig.   6 , Fig. 7, C-F) . However, whether the HBD3 is dispensable or redundant for the binding of were incubated with 1 µg/ml vitronectin and Factor H, respectively. Hic2 was coated on microtiter plates (50 µl of 10 µg/ml). In a total volume of 100 µl, Factor H (10 µg/ml) was incubated with increasing concentrations of vitronectin (Vn, 0-1 µg/ml) (C), or vitronectin (5 µg/ml) was combined with increasing amounts of Factor H (0-1 µg/ml) (D). Bound vitronectin was detected with anti-human vitronectin antiserum, followed by incubation with HRP-conjugated anti-rabbit antibodies. Bound
Factor H was detected using anti-human Factor H antiserum, followed by incubation with HRP-conjugated anti-goat IgG. 1,2-phenylenediamine dihydrochloride was used as a substrate and the absorbance was measured at 492 nm.
In A, C, and D, the mean values of at least three independent experiments are shown with error bars corresponding to SD. n.s., not significant. A-D) Hic2 was coated on microtiter plates (100 µl of 5 µg/ml) and binding of vitronectin (100 µl of 5 µg/ml) was measured in the presence of increasing concentrations of NaCl (0-1 M) (A), heparin (0-100 µg/ml) (B), heparan sulfate (0-100 µg/ml) (C), chondroitin sulfate A (0-1000 µg/ml) (D), and hyaluronic acid (0-1000 µg/ml) (E), respectively. Bound vitronectin was detected as described in Figure 3 .
Results are shown as the mean values ± SD of at least three independent experiments. *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001. A) Hic2 (100 µl of 5 µg/ml) or Factor H (100 µl of 50 µg/ml) was immobilised over night on a microtiter plate. Thereafter, immobilised Hic2 was pre-incubated with increasing concentrations of vitronectin (Vn; 100 µl of 0-50 µg/ml). Afterwards, the terminal complement proteins C5b-6, C7, C8, and C9 were sequentially added to the indicated wells, and TCC formation was detected using anti-human C5b- N039  sputum  pneumonia  I2815  blood  pneumonia  I2830  blood  pneumonia  I2844 blood pneumonia, prostate cancer, and CRI a, National Reference Center for Streptococci, Aachen, Germany. b, Non-invasive ('N') and invasive ('I') strains. COPD, chronic obstructive pulmonary disease; CRI, chronic renal insufficiency. 
